Related Experiment Video

Updated: Mar 30, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.3K

Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression

Gong-Quan Li1,2, Wen-Zhi Guo1, Yi Zhang3,4

  • 1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Oncotarget
|November 18, 2015
PubMed

Insights

Bromodomain 4 (BRD4) inhibition shows promise for treating hepatocellular carcinoma (HCC). Suppressing BRD4 reduces cancer cell growth and induces apoptosis, slowing tumor progression in mice.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Bromodomain 4 (BRD4) is an epigenetic regulator implicated in various cancers.
  • Hepatocellular carcinoma (HCC) is a significant global health concern with limited targeted therapies.

Purpose of the Study:

  • To investigate BRD4 as a potential therapeutic target for human HCC.
  • To elucidate the mechanisms underlying BRD4 inhibition in HCC treatment.

Main Methods:

  • BRD4 expression analysis in HCC tissues.
  • In vitro studies using siRNA and the BRD4 inhibitor JQ1 on HCC cell lines.
  • In vivo studies using HCC xenograft mouse models.
  • Analysis of cell cycle regulators and apoptosis markers (MYC, CDKN1B, BCL2L11).

Main Results:

  • BRD4 is overexpressed in HCC tissues.
  • BRD4 suppression via siRNA or JQ1 inhibited HCC cell growth and induced apoptosis.
  • JQ1 treatment slowed HCC xenograft tumor growth in mice.
  • JQ1 induced G1 cell cycle arrest by repressing MYC and up-regulating CDKN1B (P27).
  • JQ1 de-repressed pro-apoptotic BCL2L11 (BIM), crucial for JQ1's anti-HCC effects.

Conclusions:

  • BRD4 is a promising therapeutic target for HCC.
  • BRD4 inhibition by JQ1 exerts anti-cancer effects through cell cycle arrest and apoptosis induction.
  • BIM plays a critical role in mediating the anti-HCC activity of BRD4 inhibition.
Keywords:
BIMBRD4HCCJQ1MYC

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines08:50

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

1.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.2K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K